Conjugation of MUC1 peptide to KLH
Covalent attachment to KLH was achieved with m-malemidobenzoyl-N-hydroxysuccinimide ester (Pierce Co., Rockford, IL, USA) which couples the terminal cysteine on the MUC1 peptide to amino groups on KLH. The MBS-dimethylformamide is mixed with KLH and the unconjugated MBS eliminated by passage over a G25 sephadex column. The malemide-activated KLH was then added to the MUC1 peptide and, following a 3-h incubation, the free peptide was eliminated using a 30 000 MW centriprep filter as previously described (Amicon Inc., Beverly, MA, USA) (Zhang et al, 1996) . The resultant conjugant was washed and tested for sterility, purity and safety. The ratio of MUC1 peptide molecules per KLH molecule was 540 to 1.
Patients and treatment schedule
Sera from the initial six patients in a larger MUC1 vaccination trial were studied. Patients with AJCC stage I-III breast cancer and rising CA15.3 or CEA markers, and patients with AJCC stage IV breast cancer who were currently free of disease, were vaccinated. Accrual of patients was done under an IRB-approved protocol. MUC1-KLH conjugate containing 100 µg of MUC1 plus 100 µg QS-21 was administered subcutaneously at weekly intervals for three doses, followed by a 4-week break and then a fourth vaccination. This was followed by a 3-month break and a fifth vaccination.
Enzyme-linked immunosorbent assay (ELISA)
ELISAs were performed using alkaline-phosphatase conjugated goat anti-(human) IgM (Kierkegaard and Perry Labs, Gaithersburg, MD, USA) as previously described (Zhang et al, 1996) . To detect IgG against MUC1, an unlabelled mouse antihuman IgG (Southern Biotech, Birmingham, AL, USA) was used followed by alkaline-phosphatase labelled goat anti-mouse IgG (Southern Biotech). A total of 0.2 µg of MUC1 peptide was plated using carbonate buffer (pH 10) into Nunc (Nunc, Denmark) 96-well plates. Absorbance was measured at 414 nm and the highest serum dilution with an absorbance of at least 0.100 was defined as the antibody titre. Plates were incubated before measuring absorbance, at 37°C for approximately 20 min. Inhibition ELISAs were performed to determine more sensitively the specificity of the antibodies. For these assays, the designated amount of peptide was incubated with patient sera for 1 h and the mixture then tested on the 30 aa MUC1 peptide by ELISA. Percentage inhibition was calculated on the basis of the difference in absorbance from the uninhibited serum.
% inhibition = absorbance of uninhibited serumabsorbance of inhibited serum/ absorbance of uninhibited serum
In Figures 1 and 2 , error bars have been calculated and added to account for variability between experiments and reproducibility of the data. For each peptide at each of the concentrations, the mean value of percent inhibition within four different repeats of experiments was calculated and then error bars were calculated to reflect the variability of the mean at that concentration, as previously described (Woolson, 1987) .
Flow cytometry
Tumour cells (1 × 10 7 ) were incubated with 20 µl of 1:10 diluted sera or 1:2 diluted mAb supernatant on ice for 30 min. After washing with 3% fetal calf serum (FCS), the cells were incubated with 20 µl of 1:25 diluted fluorescence in situ hybridization (FITC)-labelled goat anti-human IgM or IgG (Southern Biotech. Assoc. Inc., Birmingham, AL, USA). The positive population of cells was quantitated by flow cytometry (Becton Dickinson FACSCAN, Sanjose, CA, USA). Pre-vaccination sera was used to set the gate at 10% background for each post-vaccination sample.
RESULTS

Direct tests
Antibody titres against MUC1 were measured by ELISA. High titre IgM and IgG antibodies against MUC1 peptide were induced in all patients. Pre-vaccination serum titres were low in all patients, except patient 6 who had a pretreatment IgM titre of 1:160 (see Table 1 ). MCF-7 cells, which express MUC1 antigen, were also used as targets in FACS analysis (Table 1) to determine whether the induced anti-MUC1 antibodies were reactive with the cell surface. Patients 1, 3, 5 and 6 showed moderately increased IgM reactivity after immunization. Weak anti-MUC1 IgG reactivity against MCF-7 cells was induced in patients 1, 2 and 3. HMFG-2, the positive control MUC1 mAb, reacted strongly with 75% of MCF-7 cells.
Inhibition tests
Sera from immunized patients were incubated (inhibited) with various amounts of small MUC1 peptides. The ELISA results obtained with sera (inhibited or not) from patient 2 are shown in Figures 1 and 2 . Complete inhibition of all IgM and IgG reactivity was achieved with the APDTRPA peptide, or longer peptides containing the full APDTRPA epitope at the C-terminal position. Partial inhibition of IgM reactivity was seen with the peptide containing APDTRPA in mid peptide. No inhibition was seen when the full APDTRPA was not present. Tables 2 and 3 summarize the IgM and IgG inhibition results for all six patients. Table 2 shows that the specificity of induced anti-MUC1 IgM antibodies was almost exclusively for a terminal APDTRPA epitope in all six patients. Only serum of patient 1 showed slight inhibition of IgM reactivity with peptide when the APDTRPA epitope was in mid peptide. Table 3 shows the specificity of the induced anti-MUC1 IgG antibodies. Here again strong inhibition was seen with the 30 aa MUC1 peptide and other peptides with a terminal APDTRPA epitope, in all six patients. However, some inhibition was also seen when the APDTRPA was present in the middle of the peptide. In addition, sera of patients 5 and 6 showed 1+ inhibition with a peptide consisting of only the APDTR epitope, and sera of patients 4, 5 and 6 showed 1+ inhibition with a peptide that had no APDTRPA sequence. Monoclonal antibody HMFG-2 was inhibited with peptides that have APDTRPA epitope regardless of its location. In addition, complete inhibition of HMFG-2 reactivity was also possible with PDTRPAPGSTAPPAH, unlike any of the immune sera, which all required the full APDTRPA epitope for complete inhibition.
DISCUSSION
The structure of the MUC1 core protein consists of an N-terminal protein sequence, followed by a variable number of tandem repeats (VNTR) of the 20 aa peptide and, finally, the transmem- 3+  4+  4+  3+  4+  4+  PAHGVTSAPDTRPA  4+  4+  3+  4+  4+  3+  3+  APDTRPA  4+  3+  3+  4+  4+  3+  3+  VTSAPDTRPAPGS  1+  0 Grading scale: percent inhibition of 85-90% was given a grade of 4+, 70-85% was a 3+, 40-70% was 2+, 20-40% was 1+, below 20% was 0. 4+  4+  4+  4+  4+  4+  PAHGVTSAPDTRPA  4+  4+  3+  4+  4+  4+  2+  APDTRPA  3+  3+  3+  4+  4+  4+  4+  VTSAPDTRPAPGS  2+  1+  1+  2+  2+  2+  4+  PDTRPAPGSTAPPAH  0  0  0  1+  1+  0  4+  PAPGSTAPPAHGVTS  0  0  0  1+  1+  1+  0  PAHGVTS  0  0  0  0  0  0  0  TSAPDTR  0  0  0  0  1+  1+  0  APDTR  0  0  0  0  1+  1+  0 Grading scale: percent inhibition of 85-90% was given a 4+ grade, 70-85% was 3+, 40-70% was 2+, 20-40% was 1+, below 20% was 0.
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British Journal of Cancer (1999) Figure 2 Inhibition of anti-MUC1 IgG reactivity in post-immunization serum of patient 2. The inhibitory peptides were VTSAPDTRPAPGS, PDTRPAPGSTAPPAH, PAPGSTAPPAHGVTS, PAHGVTSAPDTRPA, PAHGVTS, APDTRPA, APDTR, TSAPDTR and MUC1 (30 aa). Peptides were used at various concentrations to inhibit anti-MUC1 IgG reactivity and then tested by ELISA to measure percent inhibition. MUC1 peptide was coated in each well at 0.2 µg per well. The serum was used at a dilution of 1:320 brane region and cytoplasmic tail (Price et al, 1990 ). The VNTR region seems to be the most immunogenic region with the APDTRPA sequence being especially immunogenic. We have synthesized a synthetic peptide 30 amino acids long that contains 1.5 tandem repeats. This MUC1 peptide has two APDTRPA sequences: one toward the -NH 2 -terminal (but not at the terminal end) and the other at the -COOH-terminal. KLH is conjugated to the -NH 2 -terminal. Inhibition results with high titre immune sera drawn from breast cancer patients after vaccination indicated that the anti-MUC1 IgM antibodies generated against this vaccine were inhibited specifically and exclusively with peptides that have the full APDTRPA epitope present terminally. The IgG anti-MUC1 antibodies also reacted preferentially with the terminal APDTRPA epitope, but weak reactivity was also seen when the APDTRPA epitope was present in the middle of the peptide and with other portions of the MUC1 peptide. The antibodies induced in breast cancer patients against this synthetic MUC1 fail to react strongly with mucin on tumour cells. Comparing the reactivity of monoclonal antibody HMFG-2 to these MUC1 anti-sera, HMFG-2 was inhibited by PDTRPA peptide regardless of whether it was expressed terminally or in the middle of the peptide, and HMFG-2 reacted strongly with tumour mucins. Studies of the secondary structure of the protein mucin core of MUC1, suggest that the protein undergoes a β turn which results in the PDTRPAP epitope expressed at the surface of the mucin molecule where it is accessible to antibodies while much of the rest of the VNTR repeat lies buried within the helix (Price, 1988; Price et al, 1990; Price and Tendler, 1993) .
The goal of our MUC1 vaccination programme was to induce antibodies that react well with both the synthetic immunogen and tumour cells, like mAb HMFG-2. Based on the results presented here, hypotheses for the relatively modest reactivity of our immune sera with tumour MUC1 are first that the N-terminal alanine, in APDTRPA is not accessible in natural mucins. This alanine is necessary for recognition by our immune sera, but not by HMFG-2. Second, in addition to making the N-terminal alanine of APDTRPA inaccessible, the secondary structure with its β turns assumed by natural MUC1 may have other consequences in terms of the way the individual amino acids in APDTRPA are exposed or the way multiple APDTRPA epitopes in close proximity are recognized by the immune system. Third, the sequence RPA must be at the C-terminal end for strong recognition by our sera, but this is not necessary for HMFG-2 and never occurs in tumour MUC1 (Price et al, 1990 ). The MUC1 vaccine tested here contained two APDTRPA epitopes, but the APDTRPA at the -COOH-terminal may have been the only one exposed to the immune system, since the other APDTRPA epitope was adjacent to the conjugation site and may have been obstructed due to its proximity to KLH.
We have addressed these three hypotheses with two responses. First, by constructing a 32 aa MUC1 peptide containing two copies of the APDTRPA repeat, neither of which is at the C-terminal end, to force the immune system to recognize the APDTRPA epitope in the middle of the peptide as it occurs naturally. Second, by constructing a 106 aa MUC1 peptide which should naturally assume a β helix configuration similar to the proposed configuration on tumour cells. This should force the immune system to focus on multiple copies of the 20 aa repeat, to see PDTRPA and other potential epitopes in a more natural configuration. In both cases the peptides will be linked to KLH and mixed with QS-21 and the vaccines administered to breast cancer patients in the adjuvant setting. Supporting this approach, Karanikas et al (1997) , have vaccinated patients with a 106 aa MUC1 peptide conjugated to mannan (polymanose). They have reported that most of the antibodies in these studies recognized non-APDTRPA epitopes such as STAPPAHG and PAPGSTAP (Karanikas et al, 1997) . It therefore seems possible that vaccination with a longer peptide might result in recognition of additional epitopes.
A fourth hypothesis, that the peptide should be partially or completely glycosylated before the proper secondary structure is assumed, will be more difficult to address. There are differing points of view on the proper carbohydrate epitopes and glycosylation sites (Stadie et al, 1995; Karsten et al, 1998) , preparation of sufficient glyosylated MUC1 for clinical trials is difficult, and the murine response to vaccination with the same MUC1-KLH vaccine described in this study was high titre IgM and IgG antibodies that reacted strongly with MCF-7, so experiments in the mouse will not be helpful (Zhang et al, 1996) . In addition, Apostolopoulos et al (1998) have suggested that presence of antigal antibodies, which are present in humans, but not the mouse, affects the immune response against MUC1. Consequently, only trials in humans can identify the correct hypothesis and the appropriate vaccine.
